Updated

Researchers found that blocking a protein called IL1RAP disrupts an inflammatory network that helps pancreatic tumors resist treatment, according to preclinical experiments. The approach reduced tumor-protecting cells and fibrosis while boosting the activity of cancer-fighting T cells. The findings suggest that combining IL1RAP-blocking therapies with existing chemotherapy or immunotherapy regimens could improve treatment outcomes for pancreatic cancer, one of the most treatment-resistant and deadly cancers, though further clinical validation is needed.